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Background: Type 2 diabetes mellitus and depression are highly prevalent diseases that are associated with an
increased risk of cardiovascular disease and mortality. There is evidence about a bidirectional association between
depressive symptoms and type 2 diabetes mellitus. However, prognostic implications of the joint effects of these
two diseases on cardiovascular morbidity and mortality are not well-known.
Method/design: A three-year, observational, prospective, cohort study, carried out in Primary Health Care Centres
in Madrid (Spain). The project aims to analyze the effect of depression on cardiovascular events, all-cause and
cardiovascular mortality in patients with type 2 diabetes mellitus, and to estimate a clinical predictive model of
depression in these patients.
The number of patients required is 3255, all them with type 2 diabetes mellitus, older than 18 years, who regularly
visit their Primary Health Care Centres and agree to participate. They are chosen by simple random sampling from
the list of patients with type 2 diabetes mellitus of each general practitioner.
The main outcome measures are all-cause and cardiovascular mortality and cardiovascular morbidity; and exposure
variable is the major depressive disorder.
There will be a comparison between depressed and not depressed patients in all-cause mortality, cardiovascular
mortality, coronary artery disease and stroke using the Chi-squared test. Logistic regression with random effects will
be used to adjust for prognostic factors. Confounding factors that might alter the effect recorded will be taken into
account in this analysis. To assess the effect of depression on the mortality, a survival analysis will be used
comparing the two groups using the log-rank test. The control of potential confounding variables will be
performed by the construction of a Cox regression model.
Discussion: Our study’s main contribution is to evaluate the increase in the risk of cardiovascular morbidity and
mortality, in depressed Spanish adults with type 2 diabetes mellitus attended in Primary Health Care Setting. It
would also be useful to identify subgroups of patients for which the interventions could be more beneficial.
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Type 2 diabetes mellitus (T2DM) is a highly prevalent
chronic disease which affects more than 10% of the adult
population of the developed countries [1,2], and between
70% and 80% of people with diabetes die as a result of
cardiovascular complications [3-7].
Depression is also highly prevalent, approximately
5.8% of men and 9.5% of women will experience a de-
pressive episode in a year [8]. There is also evidence to
suggest that depression is associated with a significantly
increased risk of cardiovascular disease [9] and all-cause
mortality [10].
The prevalence of depression in patients with T2DM
is near twice greater than for non-diabetic subjects
[11,12]. There is a strong body of evidence for the asso-
ciation of T2DM with depression [11-13], and both dis-
eases are associated with unemployment and problems
with work performance [14].
However, data evaluating prognostic implications of
the joint effects of these two diseases on cardiovascular
disease and mortality are sparse.Depression and diabetes: bidirectional relationship
Although there is ample evidence about a bidirectional
association between depressive symptoms and T2DM
[15], there is a controversial gap in the direction of the
cause-effect [16,17], and, also the casual factors that are
intermediate in the relationship remain unclear [18].
Several studies have examined whether depression is a
predictor for the onset of T2DM, most of which confirm
an increase of risk of T2DM in depressed patients, but
differ in the extent of this increase that ranges between
32% and 60% [15,17,19,20].
On the other hand, several studies assessed if the
T2DM may also increase the risk for depression. In the
absence of comorbidities and complications, the data
showed relationship between T2DM and the onset of
depression [15-17]; with an incidence estimate among
15% to 24% [15,16,18]; after controlling for potential
confounders factors, the T2DM is associated with an
increased risk of depression (Odds Ratio (OR) = 1.41)
[20].Clinical and socioeconomic impact of the depression in
patients with DM2
The coexistence of depression and diabetes is associated
with poor adherence to treatment, dietary and weight
loss recommendations and most frequently present
other cardiovascular risk factors such as smoking, obes-
ity, sedentary lifestyle and poor glycemic control, present
a reduced health related quality of life (HRQoL), disabil-
ity and increased health care expenditures, than T2DM
patients without depression [10,21-24].Previous studies have shown that comorbid depres-
sion in diabetic patients was associated with a signifi-
cant increase of risk of macrovascular complications
(OR: 2.64) [25], microvascular complications (OR: 11.32)
[23] and is associated with an increase in risk of all-
cause mortality (OR: 1.33-1.52), after controlling for
sociodemographic factors and clinical severity of illness
[26-30].
Thus, there is an additional increase in health-service
costs of 50% in diabetes with comorbid depression [9].
Predictors of depression in T2DM patients
Few studies have been conducted to develop and validate
predictive models of depression in patients with T2DM.
The Pathways Epidemiology Study [31] showed that the
risk of major depression among patients with T2DM is
increased by depression history, baseline diabetes symp-
toms, and previous cardiovascular disease. Recently, the
results of a small study with 90 outpatients, which
examine psychosocial and clinical variables associated
with depression in T2DM patients, showed that depres-
sion in diabetic patients was predicted by diabetes
related distress, life events and neuropathy [32]. In the
predictD Study, King and colleagues elaborated a risk al-
gorithm for depression that included different variables
such as age, sex, educational level, personal and family
history of psychological difficulties, HRQoL, and social
support, among others [33]. However, frequently, studies
in this research area not included the factors identified
in the predictD Study for onset of depression in adult
general population.
Until now, the mechanisms linking depression and
T2DM are still not sufficiently known.
In sum, there is evidence that depression is associated
with T2DM, and this interaction increased mortality,
complications, and disability, as well as an earlier occur-
rence of all these adverse outcomes. However, previous
investigations have been limited by the use of self-
reported scales or data from National Health Surveys,
with a limited value as diagnostic tool. The mechanisms
linking these diseases are not well-known and it would
be useful to have a predictive clinical model to
emphasize on T2DM patients more vulnerable for de-
pression, which would enable intervention in a timely
manner to prevent or treat early those patients.
Main objectives
1. To analyze the effect of depression on cardiovascular
events (acute myocardial infarction and stroke), all-
cause and cardiovascular mortality in patients with
T2DM after 3 years follow-up.
2. To estimate a clinical predictive model of depression
in patients with T2DM.
de Burgos-Lunar et al. BMC Psychiatry 2012, 12:95 Page 3 of 8
http://www.biomedcentral.com/1471-244X/12/95Secondary objective
To determine the prevalence and the incidence rate,




A three-year, observational, prospective, cohort study,
carried out from January 1st 2011 to 31th December
2013.
Setting
The study will be carried out in 75 Primary Health Care
Centers (PHCC) in the region of Madrid, Spain.
Subjects of the study
Subjects with diagnosis of T2DM in their computerized
clinical records (CCR) and are usually monitored by
their process in PHCC.
All PHCC in Madrid have CCR available since 2003
and the diagnoses of diabetes recorded in these have
been validated [34].
Inclusion criteria
– 18 years of age or older at the date of January 1st
2011.
– Patients who had visited their PHCC at least twice
in the last year.
– Agree to participate in the study and written
informed consent.
Exclusion criteria
– Diagnosis of gestational diabetes mellitus.
– Institutionalized patients.
– Subjects who cannot understand Spanish.
– Patients with severe chronic diseases or significant
physical or psychic disabilities that might invalidate
informed consent or interview (according to clinical
judgment).
– Legal incompetence or legal guardianship.
– Participation in clinical trials.
Sample size
Method of calculation
For the first main objective, for an alpha of 0.05, a power
of 80%, a prevalence of depression of 17.6% [13] and in
order to detect an increase of 25% [25] in the mortality
of depressed patients, the overall sample size required
2959 patients. Given these assumptions, and expecting a
10% loss rate, the final sample size required was 3255
patients.The sample size considerations regarding mortality are
based on the results of Schramm in a 5-year follow-up
study [35], corrected for a 3-year period.
The sample size required to perform the other objec-
tives of the study is lower, so the sample size estimated
enables to address all the above objectives.
Randomization
Patients with T2DM will be selected by simple random
way from the patients with T2DM of each participating
general practitioner.
During consultations, patients will be informed about
the study and asked whether they would like to take
part in it. Those who accept will be asked to complete
a signed consent form. Checks will be made to ensure
they met all inclusion criteria, but no exclusion
criterion.
Variables
– The main outcome measures are all-cause and
cardiovascular-specific mortality and cardiovascular
morbidity (acute myocardial infarction, and stroke).
– The exposure variable is the major depressive
disorder.
– Sociodemographic variables: age (date of birth),
gender, nationality, time of residence in Spain,
marital status (single, unmarried partners, married,
divorced, widowed), educational level (no studies,
primary, high school, university), employment status
(working, working with a low of three months or
more, unemployed, retired/pensioner, student,
housework and other situation), employment
(manager with over 10 employees, managers with
fewer than 10 employees, administrative, self-
employed workers and supervisors, skilled manual,
semiskilled manual and unskilled manual) and social
class (I-V) [36].
– Comorbidity variables: hypertension, heart failure,
retinopathynephropathy, neuropathy, amputations,
erectile dysfunction, and renal failure.
– Other clinical variables: family history (in the
first-degree relatives) of diabetes, diabetes duration,
and sleeps quantity and quality.
– Anthropometric variables: height, weight, hip
circumference, waist circumference, systolic blood
pressure, and diastolic blood pressure.
– Laboratory results: albuminuria, creatinine, lipid
profile, A1C and glucose.
– Personal health habits: smoking (never, former
or current smoker), physical activity level
(sedentary, moderate-intensity, vigorous-intensity,
competition-level), and drinking (0.1 through 4.9,
or 5.0 or more g/d of alcohol).
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converting enzyme inhibitors, angiotensin receptor
blockers, calcium channel blockers, diuretics,
antiplatelets, antidiabetics, antidepressant drugs and
anxiolytics which were prescribed.
– Psychosocial variables: family history (in the first-
degree relatives) of psychiatric disorder, personal
history of psychiatric disorder, previous and current
therapeutic plan, current generalized anxiety
disorder, social support, and HRQoL.
The variables and their instrument of measurement
are summarized in Table 1.Data collection method
The Figure 1 shows the flowchart of the study.General practitioners
Medical evaluation will be performed under normal clin-
ical practice conditions, and clinical variables, anthropo-
metric measures, treatments and laboratory results will
be collected by general practitioners at baseline and an-
nually during follow-up. These data will be recorded in
an electronic Case Report Forms (eCRF) hosted in the
website www.madiabetes.com.Table 1 Variables and measurement instruments
Endpoint Measuring instrument S
Cardiovascular events eCRF completed with the CCR G
Mortality and cause of death Death certificateFamily reported G
N
In
Major depressive disorder MINI In
Generalized anxiety disorder MINI In
Sociodemographic variables Self-report questionnaire In
Personal health habits Self-report In
Anthropometric variables eCRF completed with the CCR G
Comorbidity and complications eCRF completed with the CCR G
Laboratory results eCRF completed with the CCR G
Treatment eCRF completed with the CCR G
Sleep quantity Self-report In
Sleep quality AIS In




Social support First item of RSE In
HRQoL SF-12 In
eCRF: electronic case report forms; CCR: computerized clinical records; MINI: Mini-Int
Form Health Survey.Clinical psychologist interview
Different questionnaires and a psychological evaluation
will be conducted by clinical psychologists at baseline
and annually during follow-up through a telephone
interview. The following variables will be collected by
this way: current major depressive disorder, generalized
anxiety disorder, personal and family history of psychi-
atric disorder, sociodemographic variables, social sup-
port, HRQoL, sleep quantity and quality.
The conversation protocol will be designed in advance
and the interviewers will receive homogeneous training
in the evaluation procedure of the study in order to
minimize the variability in the data collection.
The diagnosis of a current major depressive disorder
will be conducted through a semi-structured interview
to detect those who meet the Diagnostic and Statistical
Manual of Mental Disorders-Fourth Edition (DSM-IV)
criteria (codes: 296.26-299.20) [37]. To meet criteria for
depression patients it is required to have at least 5 symp-
toms, including at least one of the cardinal symptoms:
depressed mood or anhedonia, during two-week period.
The interview will be based on the module of major de-
pressive disorder of the Mini-International Neuropsychi-
atric Interview (MINI) [38], and according to clinical
judgment. The use of antidepressant medication in pre-
vious three months will also be used as a measure of
depression.ources Baseline Year 1 Year 2 Year 3




✓ ✓ ✓ ✓
terview by psychologist ✓ ✓ ✓
terview by psychologist ✓ ✓ ✓
terview by psychologist ✓
terview by psychologist ✓ ✓ ✓ ✓
eneral practitioners ✓ ✓ ✓ ✓
eneral practitioners ✓ ✓ ✓ ✓
eneral practitioners ✓ ✓ ✓ ✓
eneral practitioners ✓ ✓ ✓ ✓
terview by psychologist ✓ ✓ ✓ ✓
terview by psychologist ✓ ✓ ✓ ✓
terview by psychologist ✓
eneral practitioners
terview by psychologist ✓ ✓ ✓
terview by psychologist ✓ ✓ ✓




GPs invited to participate
GPs consent to participate GPs declined to participate
or did not response
All patients with T2DM
Declined to participate































Figure 1 Flowchart. GPs: General Practitioners; T2DM: Type 2 diabetes mellitus; eCRF: electronic case report forms; CCR: computerized clinical
records; NDI: National Death Index.
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will be performed by a semi-structured interview to de-
tect those who meet the DSM-IV criteria (code 300.02).
To meet criteria for this disorder, patients required to
have at least 3 of the central symptoms of anxiety (feel-
ing wound-up, tense, or restless easily becoming fatigued
or worn-out, concentration problems, irritability, signifi-
cant tension in muscles or difficulty with sleep), at least
6 months. The interview will be based on the module of
generalized anxiety disorder of the M.I.N.I. [38] and
according to clinical judgment.
The MINI is a short and efficient diagnostic interview to
diagnose mental disorders, compatible with Internationaldiagnostic criteria, including the International Classifica-
tion of Diseases (ICD-10) and the DSM-IV. It has been
validated in Spain [39], and previously has been used in
T2DM patients [40], and by telephone [41-43].
Personal history of psychiatric disorder will be regis-
tered if patient reports a positive response to the ques-
tion: “A clinician has ever diagnosed you as having any
psychiatric disorder? or there is a diagnosis prior to
baseline in the in CCR.
The diagnosis of family history of psychiatric disorder
will be registered if the patient reports a positive response
to the question: “Has any family member (in first-degree
relatives) ever been diagnosed of psychiatric disorder?”
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“About how many close friends and close relatives do
you have (people you feel at ease with and can talk to
about what is on your mind)?”, which corresponds to
the first item of the Medical Outcomes Study-Social
Support Survey (MOS-SSS) [44].
To assess the HRQoL, the Medical Outcomes Study
12-Item Short-Form Health Survey (SF-12) [45] will be
used. SF-12 is used as a generic measurement of global
functioning and HRQoL, is non-disease specific and
comprises 12 questions about the physical health com-
ponent (physical functioning and role limitations due to
physical health) and the mental health component (bod-
ily pain, vitality, social functioning, role limitations due
to emotional problems, and mental health).
The self-reported of sleep quantity will be measured
by the question: “What was the average amount of sleep
per night (in hours) and per day (in hours), during the
previous month?”. Sleep quality will be measured by the
Athens Insomnia Scale (AIS) [46]. The AIS is a self-
assessment psychometric instrument designed for quan-
tifying sleep difficulty, and its consistency, reliability, and
validity has been ascertained as a screening or diagnosis
tool for insomnia.
Assessment of vital status and death cause
Vital status and death cause will be obtained using data
collected by general practitioners, by the telephone
interview and it will be ascertained using confidential
record linkage with the Spanish National Death Index.
Loss to follow-Up
A low “lost to follow-up rate” will be essential for the
validity of the study. The total loss to follow-up at the
end of the study should be kept at less than 10% of the
recruited population.
In order to minimize the losses to follow-up attribut-
able to general practitioners whom do not continue in
the study clinical data will be provided from CCR of
patients.
If any patient changes of domicile, an official address
search via the local health administration will be
conducted.
In order to minimize losses attributable to a fail in lo-
cate the patient, up to six telephone calls will be made at
different times and on different days; after six failed
calls, will try to contact the patient by the general
practitioners.
Statistical analysis
The following analyses will be undertaken:
Descriptive analysis of each variable. Description of
the profile of patients who abandon the study plus their
reason for withdrawal.Comparison between depressed and not depressed
patients with regards to response variables, and predic-
tion factors. Bivariate statistical tests will be used suit-
able to the type of variable (qualitative or quantitative).
Analysis of primary outcome. There will be a com-
parison between depressed and not depressed patients in
all-cause and cardiovascular mortality, acute myocardial
infarction and stroke using the Chi-squared test.
Logistic regression with random effects will be used to
adjust for prognostic factors. Confounding factors that
might alter the effect recorded will be taken into account
in this analysis.
To assess the effect of depression on the mortality, a
survival analysis will be used comparing the two groups
using the log-rank test. The control of potential con-
founding variables will be performed by the construction
of a Cox regression model.
All analyses will be calculated with their 95% confi-
dence interval; statistical significance will be set at
p<0.05. Statistical processing of the data will be per-
formed with SPSS© v.18 software.Ethical considerations
The study protocol was approved by the Research Ethics
Committee of the Carlos III Hospital in Madrid and met
all good clinical practice demands rights.Discussion
The Spanish National Health System offers coverage to
over 95% of the population [47] and drugs prescribed
are partially or wholly financed, chronic patients nor-
mally visiting PCHC to receive prescriptions; for this
reason we consider that the proportion of patients who
may not have been included in the randomization of our
study to be low.
On the other hand, our work may have a selection bias
associated with the participation of both health profes-
sionals and patients volunteers.
Our study’s main contribution is to evaluate the in-
crease in the risk of cardiovascular morbidity and mor-
tality, in depressed Spanish adults with T2DM attended
in Primary Health Care Setting.
If it is shown that depression is a risk factor that
increases morbidity and mortality in patients with
T2DM, would be useful to have a predictive clinical
model to emphasize our attention in those patients with
T2DM that were more prone to depression, acting in a
timely manner to prevent or treat early.
Considering the size of the population that could be
affected by these two prevalent disorders, further consid-
eration is required to design strategies aimed to provide
adequate psychological management and support among
those with longstanding diabetes and depression.
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clinicians, so that the results will be integrated into the
normal practice in management of patients with T2DM.
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